BIFIDO Co., Ltd. (KOSDAQ:238200)
2,740.00
+15.00 (0.55%)
At close: May 29, 2026
BIFIDO Revenue
BIFIDO had revenue of 2.50B KRW in the quarter ending March 31, 2026, a decrease of -49.57%. This brings the company's revenue in the last twelve months to 17.23B, up 21.95% year-over-year. In the year 2025, BIFIDO had annual revenue of 19.68B with 59.34% growth.
Revenue (ttm)
17.23B
Revenue Growth
+21.95%
P/S Ratio
1.28
Revenue / Employee
207.55M
Employees
83
Market Cap
22.05B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 19.68B | 7.33B | 59.34% |
| Dec 31, 2024 | 12.35B | -6.28B | -33.72% |
| Dec 31, 2023 | 18.63B | 4.06B | 27.82% |
| Dec 31, 2022 | 14.58B | 2.46B | 20.32% |
| Dec 31, 2021 | 12.12B | -264.16M | -2.13% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 99.01B |
| GeneBioTech Co. ,Ltd | 89.44B |
| ChoA Pharmaceutical Co., LTD. | 59.62B |
| Kyung Nam Pharm | 56.18B |
| WooGene B&G | 54.75B |
| Seoul Pharma | 51.33B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 29.66B |